PubMed

Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group.

McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, Fuleihan G el-H, Reda C, Yates AJ, Ravn P.

Ann Intern Med. 1998 Feb 15;128(4):253-61.PMID: 9471927 [PubMed - indexed for MEDLINE]Related articlesFree article

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.PMID: 10610644 [PubMed - indexed for MEDLINE]Related articlesFree article

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.PMID: 12458987 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78. PMID: 8833208 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61.PMID: 19446148 [PubMed - indexed for MEDLINE]Related articles

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.

N Engl J Med. 1998 Feb 19;338(8):485-92.PMID: 9443925 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.PMID: 7477143 [PubMed - indexed for MEDLINE]Related articlesFree article

Bisphosphonates for prevention of postmenopausal osteoporosis.

Ravn P.

Dan Med Bull. 2002 Feb;49(1):1-18. Review.PMID: 11894721 [PubMed - indexed for MEDLINE]Related articles

Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC 2nd.

Am J Med. 1996 Nov;101(5):488-501.PMID: 8948272 [PubMed - indexed for MEDLINE]Related articles

Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.

Pols HA, Felsenberg D, Hanley DA, Stepán J, Muñoz-Torres M, Wilkin TJ, Qin-sheng G, Galich AM, Vandormael K, Yates AJ, Stych B.

Osteoporos Int. 1999;9(5):461-8.PMID: 10550467 [PubMed - indexed for MEDLINE]Related articles

Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.

Adachi JD.

Can Fam Physician. 1998 Feb;44:327-32.PMID: 9512836 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevention of bone loss after withdrawal of tamoxifen.

Cohen A, Fleischer JB, Johnson MK, Brown IN, Joe AK, Hershman DL, McMahon DJ, Silverberg SJ.

Endocr Pract. 2008 Mar;14(2):162-7.PMID: 18308653 [PubMed - indexed for MEDLINE]Related articles

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.

J Bone Miner Res. 1998 Sep;13(9):1431-8.PMID: 9738515 [PubMed - indexed for MEDLINE]Related articles

Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial.

Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL; fracture intervention trial.

Diabetes Care. 2004 Jul;27(7):1547-53.PMID: 15220226 [PubMed - indexed for MEDLINE]Related articlesFree article

Osteoporosis prevention clinical study program.

Delmas P, Gimona A.

Eur J Obstet Gynecol Reprod Biol. 1996 Apr;64 Suppl:S39-45.PMID: 8732473 [PubMed - indexed for MEDLINE]Related articles

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.PMID: 18035193 [PubMed - indexed for MEDLINE]Related articles

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.PMID: 11238495 [PubMed - indexed for MEDLINE]Related articlesFree article

[The efficacy of alendronate in the prevention and treatment of postmenopausal osteoporosis]

Cheng ZQ, Yin W, Fan JY, Ma TJ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Jun;24(3):306-9. Chinese. PMID: 12905641 [PubMed - indexed for MEDLINE]Related articles

Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women.

Bell NH, Bilezikian JP, Bone HG 3rd, Kaur A, Maragoto A, Santora AC; MK-063 Study Group.

J Clin Endocrinol Metab. 2002 Jun;87(6):2792-7.PMID: 12050252 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group.

J Bone Miner Res. 2004 Jan;19(1):11-8.PMID: 14753731 [PubMed - indexed for MEDLINE]Related articles